APLT241220P7500
- 6.34
- +0.04+0.63%
Applied Therapeutics Newsroom
Buy Rating Maintained for Applied Therapeutics Amidst SORD Program Potential and Regulatory Challenges
William Blair Maintains Applied Therapeutics(APLT.US) With Buy Rating
Applied Therapeutics Price Target Cut to $8.00/Share From $13.00 by Citigroup
Applied Therapeutics Is Maintained at Buy by Citigroup
Applied Therapeutics Price Target Raised to $13.00/Share From $11.00 by Citigroup
Citigroup Maintains Buy on Applied Therapeutics, Lowers Price Target to $8
Applied Therapeutics Is Maintained at Outperform by Baird
Baird Maintains Outperform on Applied Therapeutics, Lowers Price Target to $5
RBC Capital Downgrades Applied Therapeutics to Sector Perform, Lowers Price Target to $4
Applied Therapeutics Analyst Ratings
RBC Capital Initiates Applied Therapeutics(APLT.US) With Hold Rating, Announces Target Price $12
RBC Downgrades Applied Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $12, Keeps Speculative Risk
William Blair Maintains Applied Therapeutics(APLT.US) With Buy Rating
Citi Maintains Applied Therapeutics(APLT.US) With Buy Rating, Raises Target Price to $13
RBC Capital Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $12
Baird Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $14
Positive Regulatory Outlook and Imminent PDUFA Date Justify Buy Rating for Applied Therapeutics
RBC Capital Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $12
William Blair Maintains Applied Therapeutics(APLT.US) With Buy Rating
Applied Therapeutics (APLT) Gets a Buy From William Blair